FDA Clears Sensory Medical’s RelaxisTM, First Device for Restless Leg Syndrome

-- Device Is Only Non-Pharmacologic Approach Cleared for Improving RLS Patients’ Sleep Quality --

SLEEP 2014

SAN CLEMENTE, Calif.--()--The U.S. Food and Drug Administration (FDA) has granted commercial clearance for RelaxisTM, the first non-pharmacological approach to help improve the quality of sleep in patients with primary Restless Leg Syndrome (RLS), it was announced today by Sensory Medical Inc., the company that developed the pioneering device.

According to the federal National Institute of Neurological Disorders and Stroke (NINDS), an estimated 12 million Americans may be suffering from RLS, a life-long neurological condition that causes discomfort, pain and sleep deprivation. RLS symptoms occur primarily while a person is resting, and may increase in severity during the night. Many patients find their only relief comes from physical movement, which causes sleep interruption and subsequently leads to physical fatigue, impaired mental functioning, and emotional stress.

“Our company was founded solely to find new alternatives for treating RLS, and we are pleased to be the first and only company to have a non-pharmacological approach, clinically proven and FDA cleared, to improve sleep by addressing symptoms of this devastating condition,” said Fred Burbank, M.D., Sensory Medical’s chief executive officer and an RLS sufferer himself.

Both adults and children may be affected by RLS, although the condition is twice as prevalent in women. Among the most impacted are people middle-aged or older, as symptoms tend to increase in both frequency and duration with age. In the most severe cases, RLS attacks may occur several times per night, repeatedly causing interrupted sleep and impaired daytime functioning.

To alleviate RLS symptoms, medication therapy is often prescribed, including dopaminergic agents used to treat Parkinson’s disease, anti-convulsants, narcotic opioids, and muscle relaxants and sleep medications such as Benzodiazepines. Unfortunately, some of these medications present the risk of dependence or addiction, and are considered inappropriate for certain RLS sufferers, including pregnant women and dialysis patients. NINDS reports that some drugs also have been found to actually worsen patients’ RLS symptoms over time, despite initially providing relief.

“Relaxis represents the first prescription, noninvasive, non-medication alternative for improving quality of sleep in patients with primary Restless Leg Syndrome, a significant health problem that affects millions of people each year. Until now, patients’ only options were to suffer unaided through their condition, or face the potential side effects of long-term medication therapy,” said Dr. Burbank. He added that the total RLS patient population may be considerably underestimated, as NINDS reports some individuals avoid seeking medical attention because they do not believe their condition is treatable, and the condition may be misdiagnosed as insomnia, stress, arthritis, muscle cramps, or attributed to the “normal effects” of aging.

How Relaxis Works

The Relaxis device was designed to provide physical relief of RLS while enabling the patient to remain in bed. During an RLS episode, the patient places the low-profile Relaxis pad at the site of their discomfort and chooses a vibration intensity. The device provides 30 minutes of vibratory counterstimulation, gradually ramping down and shutting off without waking the patient.

Results from two randomized, multi-center, controlled, double-blinded, prospective clinical research studies published in a peer-reviewed journal article indicated that the Relaxis device was found superior to placebo pads for improving sleep quality in patients with primary RLS.

Sensory Medical Inc. will be exhibiting the new Relaxis system, which will be available on a prescription-only basis in the U.S. starting in the third quarter of 2014, in booth #1018 at SLEEP 2014, the American Academy of Sleep Medicine’s annual meeting of the Associated Professional Sleep Societies, beginning June 2 at the Minneapolis Convention Center.

Additional details about the Relaxis system are available at Sensory Medical’s website, www.sensorymedical.com. Based in San Clemente, Calif., the privately-held Sensory Medical Inc. was formed in 2009 after the company’s CEO, Fred Burbank, M.D., began experiencing RLS and sought a mechanical solution to relieving the condition’s symptoms.

SOURCES: “Restless Legs Syndrome Fact Sheet,” NIH/National Institute of Neurological Disorders and Stroke; “Restless Legs Syndrome,” www.mayoclinic.org; Clinical Data on file, Sensory Medical Inc.

Contacts

For Sensory Medical Inc.
Laura Jackson, 714-745-9526
lauraminjackson@gmail.com
or
Ida Yenney, 818-419-0516
idayenney@gmail.com

Release Summary

Announcing FDA clearance for the Relaxis medical system from Sensory Medical Inc., the first non-pharmacological approach for primary Restless Leg Syndrome (RLS).

Sharing

Contacts

For Sensory Medical Inc.
Laura Jackson, 714-745-9526
lauraminjackson@gmail.com
or
Ida Yenney, 818-419-0516
idayenney@gmail.com